SVF Endurance (Cayman) Limited's Sale of Vir Biotechnology, Inc. Common Stock

SVF Endurance (Cayman) Limited, a 10% stockholder of Vir Biotechnology, Inc., has filed a notice of sale of common stock. The securities were acquired upon the automatic conversion of convertible preferred stock, which was acquired and fully paid for in multiple transactions from August 2017 to January 2019. The notice details the sale of 834,202 shares of common stock on October 21, 2025, with an aggregate market value of $5,230,446.54. Additionally, the filing includes information on recent sales of common stock by SVF Endurance (Cayman) Limited over the past three months, totaling 1,138,082 shares with gross proceeds of $6,830,099.44. The sales were conducted through BTIG, LLC.